It has been reported that sleep disturbance in the elderly is associated with increased cardiovascular risk, development of hypertension, impaired glucose tolerance and depressive symptoms, but what about its effect on cognitive decline and the development of dementia? Tsapanou et al. reported that sleep deprivation is associated with the development of dementia, and the mechanism is thought to be that sleep disturbance reduces the clearance of amyloid-β (Aβ) in the cerebrospinal fluid, causing an increase of Aβ and its deposition, which increases the risk of Alzheimer's disease. Billioti de Gage et al. reviewed 10 studies on the association between benzodiazepine use and dementia risk, and found that benzodiazepines increased the risk of dementia by 1.5-2 times. However, Gray et al. reported that there was an increased risk of dementia at low and moderate doses of benzodiazepines, but not at higher doses. In addition, Imfeld et al. reported that when benzodiazepines are used in the prodromal phase of dementia onset, the risk of developing dementia is increased. It is thought that benzodiazepines are used to treat sleep disturbances that occur during the prodromal phase of dementia, and as a result, benzodiazepines could be perceived as being associated with the development of dementia. Thus, no clear conclusion has been reached about the increased risk of dementia due to the use of benzodiazepines. The treatment of sleep disorders includes pharmacological treatments such as benzodiazepines, non-benzodiazepines, melatonin receptor agonists, and orexin receptor antagonists, as well as non-pharmacological approaches such as modifying sleep habits. Taking into account the relationship between sleep disturbance and dementia, treatment of insomnia should be based on a balanced combination of each.
View full abstract